Suven Life Sciences Limited has announced the dosing of the first subjects in a Phase-1 clinical trial for SUVN-I6107, a muscarinic M1 positive allosteric modulator (M1 PAM) aimed at treating cognitive disorders. The trial is being conducted in the United States under the FDA’s Investigational New Drug (IND) approval.
The Phase-1 trial is a randomized, double-blind, placebo-controlled study conducted in two parts. The single ascending dose (SAD) phase involves approximately 40 participants across five cohorts, while the multiple ascending dose (MAD) phase will include 24 participants randomized into three cohorts for a 14-day dosing period. The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of SUVN-I6107 in healthy individuals.
SUVN-I6107 has demonstrated high selectivity for the muscarinic M1 receptor, with promising results in animal studies for cognition enhancement. Suven Life Sciences owns the intellectual property rights for SUVN-I6107 globally.
The company continues to expand its pipeline of central nervous system (CNS) treatments, with seven clinical-stage assets and ongoing research across multiple indications, including Alzheimer’s disease, Parkinson’s disease, and major depressive disorders.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
